EZH2 and breast carcinoma: EZH1/2 double inhibitor has a more outstanding anti-tumor effect than EZH2 selective inhibitor114; gemcitabine/5-fluorouracil plus GSK126 combination therapy improves the efficacy of GSK126 and blocks tumor growth117; combined anti-C-C motif chemokine ligand 2 therapy may improve the efficacy of EZH2 inhibitors in breast cancer treatment.118